$MCRB News

Seres Therapeutics Q1 EPS $(2.08) Misses $(1.88) Estimate, Sales $358.000K

Seres Therapeutics Presents New Preclinical Data To Support Design, Potential Of SER-603 Cultivated Live Biotherapeutic Candidate For Inflammatory Bowel Disease

Seres Therapeutics Presents New Preclinical Data Supporting Design And Potential Of SER-603, Next-Gen Cultivated Live Biotherapeutic Candidate For Inflammatory Bowel Disease, At DDW 2026

Seres Therapeutics Announces Three Presentations To Take Place At The 2026 European Society Of Clinical Microbiology And Infectious Diseases Global Congress, April 17-21

Seres Therapeutics: Q4 Earnings Snapshot

Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Seres Therapeutics Q4 EPS $(1.76) Beats $(2.22) Estimate, Sales $438.000K Miss $5.875M Estimate

Seres Therapeutics, Inc. (MCRB) Discusses Leadership Transition, Strategic Direction and Microbiome Therapeutics Platform Prepared Remarks Transcript

Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates

Seres Therapeutics Appoints Richard N. Kender As Executive Chair And Interim CEO

Seres to lay off staff, pause top program in latest reboot

Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases

Seres Therapeutics Pauses Key Drug Study, Cuts Jobs To Save Cash

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

Seres Therapeutics Finalizes Protocol For Phase 2 Study Of SER-155 In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant With FDA

Seres Therapeutics Announces Workforce Reduction Of ~30% To Reduce Operating Costs

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

Seres Therapeutics: Strong SER-155 Data, But Dilution Risk Now Warrants A 'Hold'

Particles for Humanity Appoints Marcus Chapman as Senior Vice President and Head of Finance